Harrow

HROW

Market cap $1.58B

Overview Fund Activity

42.82 USD

+3.40

8.63%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

43.38

+0.56

1.31%

1 day

8.63%

5 days

7.32%

1 month

10.3%

3 months

35.76%

6 months

83.62%

Year to date

17.12%

1 year

-2.62%

5 years

579.68%

10 years

494.72%

About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Employees: 382

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

17% more capital invested

Capital invested by funds: $551M [Q1] → $643M (+$91.4M) [Q2]

1% more funds holding

Funds holding: 156 [Q1] → 158 (+2) [Q2]

8% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 25

3% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $16M

0.79% less ownership

Funds ownership: 58.15% [Q1] → 57.36% (-0.79%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$63

47% upside

Avg. target

$68

58% upside

High target

$76

77% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

BTIG Thomas Shrader	$63	Buy Maintained	14 Aug 2025
HC Wainwright & Co. Yi Chen	$64	Buy Maintained	13 Aug 2025
Cantor Fitzgerald Steve Seedhouse	$76	Overweight Initiated	11 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about HROW published over the past 30 days

Harrow Announces Agenda and Speakers for Investor & Analyst Day

NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below.

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow: Buy A Blend Of Value And Growth

I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, undertreated market, resulting in a 66% QoQ surge in prescriptions and rapid market penetration. Harrow's revenue growth is robust, averaging 43.7% YoY, with VEVYE expected to sustain momentum and push the company toward profitability.

Harrow: Buy A Blend Of Value And Growth

Harrow: A Classical GARP Stock

Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% upside—driven by strong revenue growth from Vevye, Byqlovi, and Iheezo. While debt refinancing is a risk, management is confident, and cash flow projections support ongoing growth and potential future acquisitions.

Harrow: A Classical GARP Stock

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $250.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is expected to close on September 12, 2025, subject to customary closing conditions.

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has commenced a private offering (the “Offering”) of $250.0 million aggregate principal amount of senior unsecured notes due 2030 (the “2030 Notes”), subject to market and certain other conditions.

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

Zacks Investment Research

Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Zacks Investment Research

Best Momentum Stock to Buy for August 15th

ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.

Best Momentum Stock to Buy for August 15th

Zacks Investment Research

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

See News Rankings

Charts implemented using Lightweight Charts™